Lyra Therapeutics Inc

NASDAQ:LYRA   9:38:14 AM EDT
7.91
-0.19 (-2.35%)
Products, Regulatory

Lyra Announces Positive Topline Results From Lantern Phase 2 Study Of LYR-210 For Chronic Rhinosinusitis

Published: 12/07/2020 13:19 GMT
Lyra Therapeutics Inc (LYRA) - Lyra Therapeutics Inc - Announced Positive Topline Results From Lantern Phase 2 Study of Lyr-210 for Chronic Rhinosinusitis (crs).
Lyra Therapeutics- 7500 Mcg Dose of Lyr-210 Achieved Statistically Significant Improvement in Composite of 4 Cardinal Symptoms of Crs.
Lyra Therapeutics Inc - 7500 Mcg Dose of Lyr-210 Achieved Statistically Significant Improvement in Snot-22 Score.
Lyra Therapeutics Inc - Co Plans an End of Phase 2 FDA Meeting in Mid-2021.
Lyra Therapeutics Inc -co Plans to Initiate a Pivotal Phase 3 Trial of Lyr-210 in Chronic Rhinosinusitis After End of Phase 2 FDA Meeting.